Neurocrine Biosciences (NBIX) 13.46 $NBIX
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Critical Alerts For Silicon Motion Technology, Pharmacyclics, 3D Systems, Walgreen, and Neurocrine Biosciences Released By InvestorsObserver
PR Newswire - Wed Jul 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SIMO, PCYC, DDD, WAG, and NBIX.
Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
PR Newswire - Tue Jul 29, 9:00AM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2014 financial results after the Nasdaq market closes on Wednesday, August 6, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday morning, August 7, 2014 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).
Global Insomnia Clinical Trials Review, H2, 2014 Featuring 10 Companies & 10 Institutes
M2 - Thu Jul 17, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xplssq/insomnia_global) has announced the addition of the "Insomnia Global Clinical Trials Review, H2, 2014" report to their offering. Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Insomnia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sanofi - Neurocrine Biosciences, Inc. - Pfizer Inc. - GlaxoSmithKline plc - Neurim Pharmaceuticals Ltd - Eisai Co., Ltd. - Actelion Ltd Clinical Trial Overview of Top Institutes / Government - University of Rochester - Duke University - U.S. Department of Veterans Affairs - Karolinska Institute - University of Pittsburgh - Brigham and Women's Hospital - Stanford University - The University of Hong Kong - Massachusetts General Hospital - National Institute of Mental Health For more information visit http://www.researchandmarkets.com/research/xp...nia_global
Women Health Market Growth Prospects for 2014 to 2018 Analyzed and Forecasts a New Research Report at Sandlerresearch.org
PRWeb - Thu Jul 17, 4:30AM CDT
In the recent past, vendors have entered into several agreements or partnerships to develop or introduce new products or drugs in the Global Women's Health market. Some of the major acquisitions include Conceptus by Bayer, Warner Chilcott by Actavis, Uteron Pharma by Watson Pharmaceuticals, and Barr Pharmaceuticals by Teva Pharmaceutical. Some of the other prominent collaborations include Bayer with EndoCeutics to develop Vaginorm for treatment of vaginal atrophy, AbbVie with Neurocrine Biosciences to develop and commercialize Elagolix, and all next-generation GnRH antagonists for women's and men's health.
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic
Neurocrine Biosciences Presenting NBI-98854 Scientific Abstracts And Posters At The International Parkinson And Movement Disorder Society's 18th Annual Congress
PR Newswire - Wed Jun 11, 6:00AM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that on June 11, 2014, two scientific posters associated with its study of NBI-98854 in Phase IIb clinical trials of tardive dyskinesia patients, will be presented at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders in Stockholm Sweden. This annual meeting brings together over 5,000 clinicians and scientists from around the world to address current topics related to movement disorders.
Acute Heart Failure - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghj865/acute_heart) has announced the addition of the "Acute Heart Failure - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Heart Failure and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Hospira, Inc. - Amgen Inc. - Neurocrine Biosciences, Inc. - Novartis AG - Bayer AG - Trevena, Inc. - PhaseBio Pharmaceuticals, Inc. - Angion Biomedica Corp. - Lee's Pharmaceutical Holdings Limited - Anexon, Inc. For more information visit http://www.researchandmarkets.com/research/gh...cute_heart
Health Care Sector Equities Coverage -- Research on Neurocrine Biosciences, PDL BioPharma, Celgene, and Array BioPharma
PR Newswire - Fri Jun 06, 6:50AM CDT
On Thursday, June 05, 2014, the NASDAQ Composite ended at 4,296.23, up 1.05%, the Dow Jones Industrial Average finished the session at 16,836.11, up 0.59% and the S&P 500 closed at 1,940.46, up 0.65%. During the trading session, all of the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.16% higher at 695.40, and the index has advanced 0.32% in the previous three months. Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), PDL BioPharma Inc. (NASDAQ: PDLI), Celgene Corp. (NASDAQ: CELG) and Array BioPharma Inc. (NASDAQ: ARRY). Free technical research on NBIX, PDLI, CELG and ARRY can be downloaded upon signing up at:
Neurocrine Biosciences To Present At The Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu May 29, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in New York City.
Major Depressive Disorder - Pipeline Review, H1 2014: Includes 30 Company Profiles
M2 - Thu May 29, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8lbldl/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alkermes - Angelini Group - Aniona - AstraZeneca - BRAINco Biopharma - Bionure - BrainCells Inc. - Cerecor Inc. - Dainippon Sumitomo Pharma - Dart NeuroScience - Edgemont Pharmaceuticals - Eli Lilly and Company - Euthymics Bioscience - F. Hoffmann-La Roche - Fabre-Kramer Pharmaceuticals - H. Lundbeck - Intas Pharmaceuticals - Johnson & Johnson - Luye Pharma Group - M's Science Corporation - Methylation Sciences - Naurex - NeurOp Corporation - Neuralstem - Neurocrine Biosciences - OPKO Health - Otsuka Holdings - PharmaNeuroBoost - Reviva Pharmaceuticals - Richter Gedeon - Sunovion Pharmaceuticals - Suven Life Sciences - Taisho Pharmaceutical Co., Ltd. - e-Therapeutics plc - nLife Therapeutics, S.L. For more information visit http://www.researchandmarkets.com/research/8l...depressive
Neurocrine Biosciences To Present At The 26th Annual Roth Conference
PR Newswire - Tue Mar 04, 1:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26th Annual Roth Conference in Laguna.
Neurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 34th Annual Health Care Conference in Boston.
Neurocrine Biosciences prices public offering at USD17.75 per share
M2 - Thu Feb 27, 5:17AM CST
US-based drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Wednesday that it has priced its public offering of 8m shares of its common stock at USD17.75 per share.
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
PR Newswire - Wed Feb 26, 8:12PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $17.75 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neurocrine, are expected to be approximately $142 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions. Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
Digirad Corporation Reports Fourth Quarter and Year-End Financial Results
GlobeNewswire - Wed Feb 26, 5:00AM CST
Digirad Corporation (Nasdaq
RAD) today reported fourth quarter earnings of $0.8 million, or $0.04 per diluted share, with total revenues of $12.5 million. Ending cash, cash equivalents and available-for-sale securities was $26.4 million.
Neurocrine Biosciences proposes public offering of 7m common shares
M2 - Wed Feb 26, 3:06AM CST
Drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Tuesday that it plans to sell 7,000,000 shares of its common stock in an underwritten public offering.
Directory of South & Central American Libraries 2013
M2 - Wed Feb 26, 2:23AM CST
This new edition of the Directory of South & Central American Libraries provide essential details on all libraries throughout South and Central America including universities, public and special libraries and including the libraries of institutes and research centres.
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
PR Newswire - Tue Feb 25, 3:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Neurocrine will also grant to the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock. Jefferies LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Neurocrine Biosciences Announces NBI-98854 Scientific Presentations at the International Parkinson and Movement Disorder Society's 18th Annual Congress
PR Newswire - Tue Feb 25, 6:30AM CST
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that two NBI-98854 scientific abstracts have been accepted for the scientific program at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders, to be held June 8-12, 2014 in Stockholm Sweden. This annual meeting draws over 5,000 experts from around the world to address current topics related to movement disorders.
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Critical Alerts For Silicon Motion Technology, Pharmacyclics, 3D Systems, Walgreen, and Neurocrine Biosciences Released By InvestorsObserver
PR Newswire - Wed Jul 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SIMO, PCYC, DDD, WAG, and NBIX.
Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
PR Newswire - Tue Jul 29, 9:00AM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2014 financial results after the Nasdaq market closes on Wednesday, August 6, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday morning, August 7, 2014 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).
Global Insomnia Clinical Trials Review, H2, 2014 Featuring 10 Companies & 10 Institutes
M2 - Thu Jul 17, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xplssq/insomnia_global) has announced the addition of the "Insomnia Global Clinical Trials Review, H2, 2014" report to their offering. Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Insomnia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sanofi - Neurocrine Biosciences, Inc. - Pfizer Inc. - GlaxoSmithKline plc - Neurim Pharmaceuticals Ltd - Eisai Co., Ltd. - Actelion Ltd Clinical Trial Overview of Top Institutes / Government - University of Rochester - Duke University - U.S. Department of Veterans Affairs - Karolinska Institute - University of Pittsburgh - Brigham and Women's Hospital - Stanford University - The University of Hong Kong - Massachusetts General Hospital - National Institute of Mental Health For more information visit http://www.researchandmarkets.com/research/xp...nia_global
Women Health Market Growth Prospects for 2014 to 2018 Analyzed and Forecasts a New Research Report at Sandlerresearch.org
PRWeb - Thu Jul 17, 4:30AM CDT
In the recent past, vendors have entered into several agreements or partnerships to develop or introduce new products or drugs in the Global Women's Health market. Some of the major acquisitions include Conceptus by Bayer, Warner Chilcott by Actavis, Uteron Pharma by Watson Pharmaceuticals, and Barr Pharmaceuticals by Teva Pharmaceutical. Some of the other prominent collaborations include Bayer with EndoCeutics to develop Vaginorm for treatment of vaginal atrophy, AbbVie with Neurocrine Biosciences to develop and commercialize Elagolix, and all next-generation GnRH antagonists for women's and men's health.
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic
Neurocrine Biosciences Presenting NBI-98854 Scientific Abstracts And Posters At The International Parkinson And Movement Disorder Society's 18th Annual Congress
PR Newswire - Wed Jun 11, 6:00AM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that on June 11, 2014, two scientific posters associated with its study of NBI-98854 in Phase IIb clinical trials of tardive dyskinesia patients, will be presented at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders in Stockholm Sweden. This annual meeting brings together over 5,000 clinicians and scientists from around the world to address current topics related to movement disorders.
Acute Heart Failure - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghj865/acute_heart) has announced the addition of the "Acute Heart Failure - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Heart Failure and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Hospira, Inc. - Amgen Inc. - Neurocrine Biosciences, Inc. - Novartis AG - Bayer AG - Trevena, Inc. - PhaseBio Pharmaceuticals, Inc. - Angion Biomedica Corp. - Lee's Pharmaceutical Holdings Limited - Anexon, Inc. For more information visit http://www.researchandmarkets.com/research/gh...cute_heart
Health Care Sector Equities Coverage -- Research on Neurocrine Biosciences, PDL BioPharma, Celgene, and Array BioPharma
PR Newswire - Fri Jun 06, 6:50AM CDT
On Thursday, June 05, 2014, the NASDAQ Composite ended at 4,296.23, up 1.05%, the Dow Jones Industrial Average finished the session at 16,836.11, up 0.59% and the S&P 500 closed at 1,940.46, up 0.65%. During the trading session, all of the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.16% higher at 695.40, and the index has advanced 0.32% in the previous three months. Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), PDL BioPharma Inc. (NASDAQ: PDLI), Celgene Corp. (NASDAQ: CELG) and Array BioPharma Inc. (NASDAQ: ARRY). Free technical research on NBIX, PDLI, CELG and ARRY can be downloaded upon signing up at:
Neurocrine Biosciences To Present At The Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu May 29, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Jefferies 2014 Global Healthcare Conference in New York City.
Major Depressive Disorder - Pipeline Review, H1 2014: Includes 30 Company Profiles
M2 - Thu May 29, 3:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8lbldl/major_depressive) has announced the addition of the "Major Depressive Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Major Depressive Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Major Depressive Disorder and special features on late-stage and discontinued projects. This report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alkermes - Angelini Group - Aniona - AstraZeneca - BRAINco Biopharma - Bionure - BrainCells Inc. - Cerecor Inc. - Dainippon Sumitomo Pharma - Dart NeuroScience - Edgemont Pharmaceuticals - Eli Lilly and Company - Euthymics Bioscience - F. Hoffmann-La Roche - Fabre-Kramer Pharmaceuticals - H. Lundbeck - Intas Pharmaceuticals - Johnson & Johnson - Luye Pharma Group - M's Science Corporation - Methylation Sciences - Naurex - NeurOp Corporation - Neuralstem - Neurocrine Biosciences - OPKO Health - Otsuka Holdings - PharmaNeuroBoost - Reviva Pharmaceuticals - Richter Gedeon - Sunovion Pharmaceuticals - Suven Life Sciences - Taisho Pharmaceutical Co., Ltd. - e-Therapeutics plc - nLife Therapeutics, S.L. For more information visit http://www.researchandmarkets.com/research/8l...depressive
Neurocrine Biosciences To Present At The 26th Annual Roth Conference
PR Newswire - Tue Mar 04, 1:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26th Annual Roth Conference in Laguna.
Neurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 34th Annual Health Care Conference in Boston.
Neurocrine Biosciences prices public offering at USD17.75 per share
M2 - Thu Feb 27, 5:17AM CST
US-based drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Wednesday that it has priced its public offering of 8m shares of its common stock at USD17.75 per share.
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
PR Newswire - Wed Feb 26, 8:12PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $17.75 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neurocrine, are expected to be approximately $142 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions. Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
Digirad Corporation Reports Fourth Quarter and Year-End Financial Results
GlobeNewswire - Wed Feb 26, 5:00AM CST
Digirad Corporation (Nasdaq
RAD) today reported fourth quarter earnings of $0.8 million, or $0.04 per diluted share, with total revenues of $12.5 million. Ending cash, cash equivalents and available-for-sale securities was $26.4 million. Neurocrine Biosciences proposes public offering of 7m common shares
M2 - Wed Feb 26, 3:06AM CST
Drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Tuesday that it plans to sell 7,000,000 shares of its common stock in an underwritten public offering.
Directory of South & Central American Libraries 2013
M2 - Wed Feb 26, 2:23AM CST
This new edition of the Directory of South & Central American Libraries provide essential details on all libraries throughout South and Central America including universities, public and special libraries and including the libraries of institutes and research centres.
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
PR Newswire - Tue Feb 25, 3:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Neurocrine will also grant to the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock. Jefferies LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Neurocrine Biosciences Announces NBI-98854 Scientific Presentations at the International Parkinson and Movement Disorder Society's 18th Annual Congress
PR Newswire - Tue Feb 25, 6:30AM CST
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that two NBI-98854 scientific abstracts have been accepted for the scientific program at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders, to be held June 8-12, 2014 in Stockholm Sweden. This annual meeting draws over 5,000 experts from around the world to address current topics related to movement disorders.
